AI's role in the Fujifilm/Hitachi acquisition

FUJIFILM Corporation announced Wednesday, Dec. 18, that it has entered into an agreement to purchase Hitachi’s diagnostic imaging business for more than $1.6 billion. AI appears to have played an important role in Fujifilm’s decision—the company will soon be able to apply its own image processing and AI capabilities to Hitachi’s own lineup of diagnostic imaging solutions.

In fact, within Fujifilm’s prepared statement on the acquisition, “providing innovation solutions by leveraging Fujifilm’s proprietary imaging processing and AI technologies” is listed as a top “intended synergy” once the deal is finalized.

“For example, the use of AI technology on CT images can reduce noise and offer better image quality in low-dose examinations,” according to the statement.  

In addition, the company says this acquisition will help Fujifilm “expand into new areas, including ‘AI-supported diagnosis’ and ‘AI-supported maintenance.’

Other “intended synergies” listed in the statement were “providing one-stop total solutions” and “expanding sales capability through cross-selling.”

Fujifilm’s acquisition of Hitachi’s diagnostic imaging business is expected to be completed in July 2020.  For more on the announcement, read the latest coverage from Radiology Business here and here.

Michael Walter
Michael Walter, Managing Editor

Michael has more than 18 years of experience as a professional writer and editor. He has written at length about cardiology, radiology, artificial intelligence and other key healthcare topics.

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.